Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial
Enriqueta Felip, Nasser K. Altorki, Caicun Zhou, Eric Vallières, Alex Martínez‐Martí, Achim Rittmeyer, Antonio Chella, Martin Reck, O. Goloborodko, Meijuan Huang, R. Belleli, Virginia McNally, Minu K. Srivastava, Elizabeth Bennett, B.J. Gitlitz, H. Wakelee
Topics & Concepts
MedicineAtezolizumabHazard ratioInterim analysisInternal medicinePopulationClinical endpointLung cancerOncologyConfidence intervalCancerSurgeryRandomized controlled trialImmunotherapyPembrolizumabEnvironmental healthCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and TreatmentLung Cancer Treatments and Mutations